Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- CRDF
- Price
- 1.56
- Stock movement down
- -0.04 (-2.50%)
- Company name
- Cardiff Oncology Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 105.08M
- Ent value
- 104.11M
- Price/Sales
- 177.20
- Price/Book
- 2.32
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -5.79%
- 1 year return (CAGR)
- -62.41%
- 3 year return (CAGR)
- -4.30%
- 5 year return (CAGR)
- -34.57%
- 10 year return (CAGR)
- -40.11%
Last updated: 2026-03-13
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
CRDF does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 177.20 |
| Price to Book | 2.32 |
| EV to Sales | 175.56 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 67.36M |
| EPS (TTM) | -0.69 |
| FCF per share (TTM) | -0.57 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 593.00K |
| Gross profit (TTM) | -11.21M |
| Operating income (TTM) | -48.96M |
| Net income (TTM) | -45.85M |
| EPS (TTM) | -0.69 |
| EPS (1y forward) | -0.70 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -1890.39% |
| Operating margin (TTM) | -8256.32% |
| Profit margin (TTM) | -7732.21% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 17.47M |
| Net receivables | 182.00K |
| Total current assets | 60.13M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 5.67M |
| Total assets | 61.88M |
| Accounts payable | 8.09M |
| Short/Current long term debt | 832.00K |
| Total current liabilities | 16.39M |
| Total liabilities | 16.50M |
| Shareholder's equity | 45.39M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -37.92M |
| Capital expenditures (TTM) | 44.00K |
| Free cash flow (TTM) | -37.97M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -101.02% |
| Return on Assets | -74.09% |
| Return on Invested Capital | -99.42% |
| Cash Return on Invested Capital | -82.33% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.59 |
| Daily high | 1.61 |
| Daily low | 1.55 |
| Daily Volume | 451K |
| All-time high | 1926.72 |
| 1y analyst estimate | 7.75 |
| Beta | 1.37 |
| EPS (TTM) | -0.69 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 26 Feb 2026 |
Downside potential
Loading...
Downside potential data
| CRDF | S&P500 | |
| Current price drop from All-time high | -99.92% | -1.82% |
| Highest price drop | -99.96% | -56.47% |
| Date of highest drop | 18 Mar 2020 | 9 Mar 2009 |
| Avg drop from high | -87.82% | -10.84% |
| Avg time to new high | 234 days | 12 days |
| Max time to new high | 4589 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
105.08M
Marketcap category
Small-cap
Description
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Employees
30
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page